Skip to main content

VALIDACION DE UNA NUEVA TERAPIA ANTI-MYC EN MELANOMA

PI19/01277

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre FUNDACION PRIVADA INSTITUTO DE INVESTIGACION ONCOLOGICA VALLE DE HEBRON- VHIO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC, there is more to it than cancer

  • Zacarías-Fluck, Mariano F.|||0000-0002-7171-4268
  • Soucek, Laura|||0000-0002-4750-7971
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
MYC is a pleiotropic transcription factor involved in multiple cellular processes. While its mechanism of action and targets are not completely elucidated, it has a fundamental role in cellular proliferation, differentiation, metabolism, ribogenesis, and bone and vascular development. Over 4 decades of research and some 10,000 publications linking it to tumorigenesis (by searching PubMed for "MYC oncogene") have led to MYC becoming a most-wanted target for the treatment of cancer, where many of MYC's physiological functions become co-opted for tumour initiation and maintenance. In this context, an abundance of reviews describes strategies for potentially targeting MYC in the oncology field. However, its multiple roles in different aspects of cellular biology suggest that it may also play a role in many additional diseases, and other publications are indeed linking MYC to pathologies beyond cancer. Here, we review these physiological functions and the current literature linking MYC to non-oncological diseases. The intense efforts towards developing MYC inhibitors as a cancer therapy will potentially have huge implications for the treatment of other diseases. In addition, with a complementary approach, we discuss some diseases and conditions where MYC appears to play a protective role and hence its increased expression or activation could be therapeutic.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MYC: there is more to it than cancer

  • Zacarias Fluck, Mariano F
  • Soucek, Laura
  • Whitfield, Jonathan
MYC; Non-oncological diseases; Transcription factor, MYC; Enfermedades no oncológicas; Factor de transcripcion, MYC; Malalties no oncològiques; Factor de transcripció, MYC is a pleiotropic transcription factor involved in multiple cellular processes. While its mechanism of action and targets are not completely elucidated, it has a fundamental role in cellular proliferation, differentiation, metabolism, ribogenesis, and bone and vascular development. Over 4 decades of research and some 10,000 publications linking it to tumorigenesis (by searching PubMed for "MYC oncogene") have led to MYC becoming a most-wanted target for the treatment of cancer, where many of MYC's physiological functions become co-opted for tumour initiation and maintenance. In this context, an abundance of reviews describes strategies for potentially targeting MYC in the oncology field. However, its multiple roles in different aspects of cellular biology suggest that it may also play a role in many additional diseases, and other publications are indeed linking MYC to pathologies beyond cancer. Here, we review these physiological functions and the current literature linking MYC to non-oncological diseases. The intense efforts towards developing MYC inhibitors as a cancer therapy will potentially have huge implications for the treatment of other diseases. In addition, with a complementary approach, we discuss some diseases and conditions where MYC appears to play a protective role and hence its increased expression or activation could be therapeutic., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Authors acknowledge funding support from the Spanish Ministry of Science and Innovation (Fondo de Investigación en Salud [FIS] PI19/01277, the State Agency for Research (Agencia Estatal de Investigación) as a Center of Excellence Severo Ochoa (CEX 2020-001024-S/AEI/10.13039/501100011033), the Generalitat de Catalunya (AGAUR 2021/SGR 01509), and the FERO foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

  • Zacarias Fluck, Mariano F
  • Massó-Vallés, Daniel
  • Giuntini, Fabio
  • González-Larreategui, Íñigo
  • Kaur, Jastrinjan
  • Casacuberta-Serra, Sílvia
  • Jauset González, Antoni
  • Martínez Martín, Sandra
  • Martín Fernández, Génesis
  • Serrano del Pozo, Erika
  • Foradada Felip, Laia
  • Grueso Gragera, Judit
  • Nonell Malezon, Lara
  • Whitfield, Jonathan
  • Beaulieu, Marie-Eve
  • Soucek, Laura
MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease., M.F.Z.-F. was supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (IJCI-2014-22403) and Fundació La Marató de TV3 (grant 474/C/2019); F.G. was supported by Spanish Ministry of Science and Innovation Contratos Predoctorales de Formación en Investigación en Salud (PFIS; FI20/00274); I.G.-L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812); and S.M.-M. was supported by the Generalitat de Catalunya “Contractació de Personal Investigador Novell (FI-DGR)” 2016 fellowship (2016FI_B 00592). This project was funded by grants from the Spanish Ministry of Science and Innovation (Fondo de Inversión en Salud [FIS] PI19/01277, which also supported I.G.-L. and S.M.-M, and Retos-Colaboración 2019 RTC2019-007067-1), La Marató TV3, the Generalitat de Catalunya AGAUR 2017 grant SGR-3193, and the European Research Council (ERC-PoC II/3079/SYST-iMYC [813132]). We thank the rest of the Soucek laboratory for critical reading of the manuscript, and the personnel at Vall d'Hebron Research Institute (VHIR) High Technology Unit. We acknowledge Vall d'Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

  • Zacarías-Fluck, Mariano F|||0000-0002-7171-4268
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Giuntini, Fabio
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Kaur, Jastrinjan|||0000-0002-4474-5093
  • Casacuberta-Serra, Sílvia|||0000-0002-2595-1115
  • Jauset, Toni|||0000-0003-2869-5804
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Martín-Fernández, Génesis|||0000-0002-1052-9763
  • Serrano del Pozo, Erika|||0000-0003-2417-1499
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Grueso, Judit|||0000-0003-1093-7940
  • Nonell, Lara|||0000-0002-8538-8213
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Soucek, Laura|||0000-0002-4750-7971
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway-the most predominantly mutated pathway in this disease-turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

  • Zacarias Fluck, Mariano F
  • Massó-Vallés, Daniel
  • Giuntini, Fabio
  • González-Larreategui, Íñigo
  • Kaur, Jastrinjan
  • Casacuberta-Serra, Sílvia
  • Jauset González, Antoni
  • Martínez Martín, Sandra
  • Martín Fernández, Génesis
  • Serrano del Pozo, Erika
  • Foradada Felip, Laia
  • Grueso Gragera, Judit
  • Nonell Malezon, Lara
  • Whitfield, Jonathan
  • Beaulieu, Marie-Eve
  • Soucek, Laura
MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease., M.F.Z.-F. was supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (IJCI-2014-22403) and Fundació La Marató de TV3 (grant 474/C/2019); F.G. was supported by Spanish Ministry of Science and Innovation Contratos Predoctorales de Formación en Investigación en Salud (PFIS; FI20/00274); I.G.-L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812); and S.M.-M. was supported by the Generalitat de Catalunya “Contractació de Personal Investigador Novell (FI-DGR)” 2016 fellowship (2016FI_B 00592). This project was funded by grants from the Spanish Ministry of Science and Innovation (Fondo de Inversión en Salud [FIS] PI19/01277, which also supported I.G.-L. and S.M.-M, and Retos-Colaboración 2019 RTC2019-007067-1), La Marató TV3, the Generalitat de Catalunya AGAUR 2017 grant SGR-3193, and the European Research Council (ERC-PoC II/3079/SYST-iMYC [813132]). We thank the rest of the Soucek laboratory for critical reading of the manuscript, and the personnel at Vall d'Hebron Research Institute (VHIR) High Technology Unit. We acknowledge Vall d'Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

MYC: there is more to it than cancer

  • Zacarias Fluck, Mariano F
  • Soucek, Laura
  • Whitfield, Jonathan
MYC; Non-oncological diseases; Transcription factor, MYC; Enfermedades no oncológicas; Factor de transcripcion, MYC; Malalties no oncològiques; Factor de transcripció, MYC is a pleiotropic transcription factor involved in multiple cellular processes. While its mechanism of action and targets are not completely elucidated, it has a fundamental role in cellular proliferation, differentiation, metabolism, ribogenesis, and bone and vascular development. Over 4 decades of research and some 10,000 publications linking it to tumorigenesis (by searching PubMed for "MYC oncogene") have led to MYC becoming a most-wanted target for the treatment of cancer, where many of MYC's physiological functions become co-opted for tumour initiation and maintenance. In this context, an abundance of reviews describes strategies for potentially targeting MYC in the oncology field. However, its multiple roles in different aspects of cellular biology suggest that it may also play a role in many additional diseases, and other publications are indeed linking MYC to pathologies beyond cancer. Here, we review these physiological functions and the current literature linking MYC to non-oncological diseases. The intense efforts towards developing MYC inhibitors as a cancer therapy will potentially have huge implications for the treatment of other diseases. In addition, with a complementary approach, we discuss some diseases and conditions where MYC appears to play a protective role and hence its increased expression or activation could be therapeutic., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Authors acknowledge funding support from the Spanish Ministry of Science and Innovation (Fondo de Investigación en Salud [FIS] PI19/01277, the State Agency for Research (Agencia Estatal de Investigación) as a Center of Excellence Severo Ochoa (CEX 2020-001024-S/AEI/10.13039/501100011033), the Generalitat de Catalunya (AGAUR 2021/SGR 01509), and the FERO foundation.